التفاصيل البيبلوغرافية
| العنوان: |
Teratogenic drugs and their drug interactions with hormonal contraceptives. |
| المؤلفون: |
Ahn, MR, Li, L, Shon, J, Bashaw, ED, Kim, M‐J |
| المصدر: |
Clinical Pharmacology & Therapeutics; Sep2016, Vol. 100 Issue 3, p217-219, 3p |
| مصطلحات موضوعية: |
TERATOGENIC agents, STEROID hormones, UNWANTED pregnancy, DRUG interactions, PREVENTION |
| الشركة/الكيان: |
UNITED States. Food & Drug Administration |
| مستخلص: |
The US Food and Drug Administration (FDA) Guidance for Industry-Drug Interaction Studies, recommends that a potential human teratogen needs to be studied in vivo for effects on contraceptive steroids.1 This article highlights the need to evaluate the drug-drug interactions (DDIs) between drugs with teratogenic potential and hormonal contraceptives (HCs) during drug development. It also addresses the FDA's effort of communicating DDI findings in product labels to mitigate the risk of unintended pregnancy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Clinical Pharmacology & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder